Rajiven Srikantharajah

Rajiven Srikantharajah

Auto-generated profile, based on publicly available information

Rajiven Srikantharajah

Department of Experimental Pharmacology and Toxicology, University Medical Centre Hamburg-Eppendorf, Germany (T.S., J.R., C.M., B.G., R.S., C.v.B., A.S., M.K., T.E., F.W.).

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Circulation
Verified
Journal Article
Open access
PDF file
TSTim Stüdemann
Tim Stüdemann
JRJudith Rössinger
Judith Rössinger
CMChristoph Manthey
Christoph Manthey
BGBirgit Geertz
Birgit Geertz
RSRajiven Srikantharajah
Rajiven Srikantharajah
FWFlorian Weinberger
Florian Weinberger
Background: Transplantation of pluripotent stem cell–derived cardiomyocytes represents a promising therapeutic strategy for cardiac regeneration, and the first clinical studies in patients with heart failure have commenced. Yet, little is known about the mechanism of action underlying graft-induced benefits. Here, we explored whether transplanted cardiomyocytes actively contribute to heart function. Methods: We injected cardiomyocytes with an optogenetic off-on switch in a guinea pig cardiac injury model. Results: Light-induced inhibition of engrafted cardiomyocyte contractility resulted in a rapid decrease of left ventricular function in ≈50% (7/13) animals that was fully reversible with the offset of photostimulation. Conclusions: Our optogenetic approach demonstrates that transplanted cardiomyocytes can actively participate in heart function, supporting the hypothesis that the delivery of new force-generating myocardium can serve as a regenerative therapeutic strategy.